Ali-Khan Sarah E, Jean Antoine, MacDonald Emily, Gold E Richard
Faculty of Law, Centre for Intellectual Property Policy (CIPP), McGill University, 3644 Rue Peel, Montreal, H3A 1W9, Canada.
Tanenbaum Open Science Institute (TOSI), Montreal Neurological Institute and Hospital, McGill University, 3801 University, Montreal, H3A 2B4, Canada.
MNI Open Res. 2018;2:2. doi: 10.12688/mniopenres.12780.2. Epub 2018 Mar 20.
Mounting evidence indicates that worldwide, innovation systems are increasing unsustainable. Equally, concerns about inequities in the science and innovation process, and in access to its benefits, continue. Against a backdrop of growing health, economic and scientific challenges global stakeholders are urgently seeking to spur innovation and maximize the just distribution of benefits for all. Open Science collaboration (OS) - comprising a variety of approaches to increase open, public, and rapid mobilization of scientific knowledge - is seen to be one of the most promising ways forward. Yet, many decision-makers hesitate to construct policy to support the adoption and implementation of OS without access to substantive, clear and reliable evidence. In October 2017, international thought-leaders gathered at an Open Science Leadership Forum in the Washington DC offices of the Bill and Melinda Gates Foundation to share their views on what successful Open Science looks like. Delegates from developed and developing nations, national governments, science agencies and funding bodies, philanthropy, researchers, patient organizations and the biotechnology, pharma and artificial intelligence (AI) industries discussed the outcomes that would rally them to invest in OS, as well as wider issues of policy and implementation. This first of two reports, summarizes delegates' views on what they believe OS will deliver in terms of research, innovation and social impact in the life sciences. Through open and collaborative process over the next months, we will translate these success outcomes into a toolkit of quantitative and qualitative indicators to assess when, where and how open science collaborations best advance research, innovation and social benefit. Ultimately, this work aims to develop and openly share tools to allow stakeholders to evaluate and re-invent their innovation ecosystems, to maximize value for the global public and patients, and address long-standing questions about the mechanics of innovation.
越来越多的证据表明，在全球范围内，创新体系正变得越来越不可持续。同样，对科学与创新过程中以及获取其利益方面存在的不平等现象的担忧依然存在。在健康、经济和科学挑战日益严峻的背景下，全球利益相关者迫切希望推动创新，并使所有人能公平地分享利益。开放科学合作（OS）——包括各种旨在促进科学知识的开放、公开和快速传播的方法——被视为最有前景的前进方向之一。然而，许多决策者在没有实质性、清晰且可靠的证据的情况下，对于制定支持采用和实施开放科学合作的政策犹豫不决。2017年10月，国际思想领袖齐聚华盛顿特区比尔及梅琳达·盖茨基金会办公室召开的开放科学领导力论坛，分享他们对于成功的开放科学合作的看法。来自发达国家和发展中国家的代表、各国政府、科学机构和资助机构、慈善机构、研究人员、患者组织以及生物技术、制药和人工智能（AI）行业，讨论了能促使他们投资开放科学合作的成果，以及更广泛的政策和实施问题。这两篇报告中的第一篇，总结了代表们对于他们认为开放科学合作在生命科学的研究、创新和社会影响方面将带来的成果的看法。在接下来的几个月里，通过开放和协作的过程，我们将把这些成功成果转化为一套定量和定性指标的工具包，以评估开放科学合作在何时、何地以及如何能最好地推动研究、创新和社会效益。最终，这项工作旨在开发并公开分享工具，使利益相关者能够评估和重塑他们的创新生态系统，为全球公众和患者创造最大价值，并解决有关创新机制的长期问题。
